Boehringer Ingelheim appoints new Regional Managing Director

United Arab Emirates,

Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced the appointment of Mohammed Tawil as Regional Managing Director for the Middle East, Turkey and Africa (META) region, in addition to his role as Head of Human Pharmaceuticals. Tawil will lead the company’s operations from its regional headquarters in Dubai, United Arab Emirates.

Prior to joining META, Tawil was a Regional Business Manager within the Emerging Markets region, based at the company’s headquarters in Germany. He was responsible for China, Mexico, Brazil and South America, where he successfully managed positive transformational changes across Boehringer Ingelheim’s Emerging Markets operations. Tawil was instrumental in supporting the expansion of the business in these markets, which represents 70% of the company’s Emerging Markets total business. He brings with him over two decades of experience combining strategic global insights with a deep knowledge and understanding of the Middle East and North Africa region, having held several leadership positions within the region. Before moving to Germany, Tawil was the General Manager for Boehringer Ingelheim Near East Middle East Area. 

As Regional Managing Director for Boehringer Ingelheim META, Tawil will focus on achieving growth and market leadership, while further developing innovative solutions that serve customers and patients across the Human Pharmaceuticals and Animal Health businesses.  

Commenting on his new role, Tawil said, “I’m excited about taking on this role and look forward to contributing to the sustainable development of the business in the region. I see tremendous potential to bring more value to the communities that we operate in through two main factors. First, that the company has a strong focus on bringing innovative solutions to patients in an effort to better serve their needs. And secondly, our region is highly responsive and open to partnerships that would reshape the overall healthcare landscape.”

Tawil believes in an inclusive leadership style that recognizes the benefit of a collaborative environment, which leverages the strengths of the team to deliver results and develop people further. “Knowledge sharing and effective teamwork are among the main driving forces in Boehringer Ingelheim. The greatest successes I have witnessed in my international career were a direct result of the combined efforts of an exceptional diverse group of professionals. I am keen to ensure that we apply this approach not only to deliver results, but to make a difference for the generations to come.”

 

-END-

About Boehringer Ingelheim

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros corresponded to 18.1 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards humankind and the environment.

For more information, please visit the company’s social media platforms for the region: Facebook or Twitter   

 

For further information, kindly contact

 

Sara Shamel

Head of External Communications - META

Boehringer Ingelheim | Middle East, Turkey and Africa

sara.shamel@boehringer-ingelheim.com